{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:23:45Z","timestamp":1770351825670,"version":"3.49.0"},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,12,15]]},"DOI":"10.2169\/internalmedicine.3271-19","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T22:03:04Z","timestamp":1566943384000},"page":"3545-3550","source":"Crossref","is-referenced-by-count":7,"title":["Osteoclast-like Giant Cell-type Pancreatic Anaplastic Carcinoma Presenting with a Duodenal Polypoid Lesion"],"prefix":"10.2169","volume":"58","author":[{"given":"Hiroyuki","family":"Matsubayashi","sequence":"first","affiliation":[{"name":"Division of Endoscopy, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Endoscopy, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Endoscopy, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Endoscopy, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Ishiwatari","sequence":"additional","affiliation":[{"name":"Division of Endoscopy, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teichi","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Division of Hepato-pancreaticobiliary Surgery, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ashida","sequence":"additional","affiliation":[{"name":"Division of Hepato-pancreaticobiliary Surgery, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Uesaka","sequence":"additional","affiliation":[{"name":"Division of Hepato-pancreaticobiliary Surgery, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Pathology, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Endoscopy, Shizuoka Cancer Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Paniccia A, Hosokawa PW, Schulick RD, et al. A matched-cohort analysis of 192 pancreatic anaplastic carcinomas and 960 pancreatic adenocarcinomas: A 13-year North American experience using the National Cancer Data Base (NCDB). Surgery 160: 281-292, 2016."},{"key":"2","unstructured":"2. Muraki T, Reid MD, Basturk O, et al. Undifferentiated carcinoma with osteoclastic giant cells of the pancreas: clinicopathologic analysis of 38 cases highlights a more protracted clinical course than currently appreciated. Am J Surg Pathol 40: 1203-1216, 2016."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Luchini C, Pea A, Lionheart G, et al. Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. J Pathol 243: 148-154, 2017.","DOI":"10.1002\/path.4941"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Clark CJ, Arun JS, Graham RP, et al. Clinical characteristics and overall survival in patients with anaplastic pancreatic cancer. Am Surg 80: 117-123, 2014.","DOI":"10.1177\/000313481408000218"},{"key":"5","unstructured":"5. Clark CJ, Graham RP, Arun JS, et al. Clinical outcomes for anaplastic pancreatic cancer: a population-based study. J Am Coll Surg 215: 627-634, 2012."},{"key":"6","unstructured":"6. Hoshimoto S, Matsui J, Miyata R, et al. Anaplastic carcinoma of the pancreas: case report and literature review of reported cases in Japan. World J Gastroenterol 22: 8631-8637, 2016."},{"key":"7","unstructured":"7. Fukukura Y, Kumagae Y, Hirahara M, et al. CT and MRI features of undifferentiated carcinomas with osteoclast-like giant cells of the pancreas: a case series. Abdom Radiol (NY) 44: 1246-1255, 2019."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yang KY, Choi JI, Choi MH, et al. Magnetic resonance imaging findings of undifferentiated carcinoma with osteoclast-like giant cells of pancreas. Clin Imaging 40: 148-151, 2016.","DOI":"10.1016\/j.clinimag.2015.09.013"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Khashab MA, Emerson RE, DeWitt JM. Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of anaplastic pancreatic carcinoma: a single-center experience. Pancreas 39: 88-91, 2010.","DOI":"10.1097\/MPA.0b013e3181bba268"},{"key":"10","unstructured":"10. Luchini C, Cros J, Pea A, et al. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Hum Pathol 81: 157-165, 2018."},{"key":"11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"11. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387: 1540-1550, 2016.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"12","unstructured":"12. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389: 255-265, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3271-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T14:01:41Z","timestamp":1610892101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/24\/58_3271-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,15]]},"references-count":12,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3271-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,15]]}}}